Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage

Published by: Datamonitor

Published: Sep. 29, 2008


Table of Contents


Please Note: Due to the brevity and/or nature of the content posted, there is no table of contents available for this report.

Abstract

Introduction

The antidyslipidemic market is expected to fall to $20 billion in 2017. The decline will be driven by the deep genericization of the market, further exacerbated by the patent expiries of the top antidyslipidemic, Pfizer's Lipitor, as well as by the recent negative messages from the ILLUMINATE and ENHANCE clinical trials.

Reasons to Purchase
  • Quantify the future size and understand the background of the antidyslipidemic market
  • Understand the commercial landscape in terms of new product potential
  • Understand the barriers to uptake for novel antidyslipidemics.


Please Note: This product is delivered as a zip file

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2012
2/15/2012 - 32